{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:57:19Z","timestamp":1790128639004,"version":"4.0.1"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>This study aimed to systematically review research on cinacalcet and secondary hyperparathyroidism (SHPT) using machine learning-based statistical analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Publications indexed in the Web of Science Core Collection database on Cinacalcet and SHPT published between 2000 and 2022 were retrieved. The R package \u201cBibliometrix,\u201d VOSviewer, CiteSpace, meta, and latent Dirichlet allocation (LDA) in Python were used to generate bibliometric and meta-analytical results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 959 articles were included in our bibliometric analysis. In total, 3753 scholars from 54 countries contributed to this field of research. The United States, Japan, and China were found to be among the three most productive countries worldwide. Three Japanese institutions (Showa University, Tokai University, and Kobe University) published the most articles on Cinacalcet and SHPT. Fukagawa, M.; Chertow, G.M.; Goodman W.G. were the three authors who published the most articles in this field. Most articles were published in <jats:italic>Nephrology Dialysis Transplantation<\/jats:italic>, <jats:italic>Kidney International<\/jats:italic>, and <jats:italic>Therapeutic Apheresis and Dialysis<\/jats:italic>. Research on Cinacalcet and SHPT has mainly included three topics: 1) comparative effects of various treatments, 2) the safety and efficacy of cinacalcet, and 3) fibroblast growth factor-23 (FGF-23). Integrated treatments, cinacalcet use in pediatric chronic kidney disease, and new therapeutic targets are emerging research hotspots. Through a meta-analysis, we confirmed the effects of Cinacalcet on reducing serum PTH (<jats:italic>SMD<\/jats:italic> = -0.56, 95% <jats:italic>CI<\/jats:italic> = -0.76 to -0.37, <jats:italic>p<\/jats:italic> = 0.001) and calcium (<jats:italic>SMD<\/jats:italic> = -0.93, 95% <jats:italic>CI<\/jats:italic> = -1.21to -0.64, <jats:italic>p<\/jats:italic> = 0.001) and improving phosphate (<jats:italic>SMD<\/jats:italic> = 0.17, 95% <jats:italic>CI<\/jats:italic> = -0.33 to -0.01, <jats:italic>p<\/jats:italic> = 0.033) and calcium-phosphate product levels (<jats:italic>SMD<\/jats:italic> = -0.49, 95% <jats:italic>CI<\/jats:italic> = -0.71 to -0.28, <jats:italic>p<\/jats:italic> = 0.001); we found no difference in all-cause mortality (<jats:italic>RR<\/jats:italic> = 0.97, 95% <jats:italic>CI<\/jats:italic> = 0.90 to 1.05, <jats:italic>p<\/jats:italic> = 0.47), cardiovascular mortality (<jats:italic>RR<\/jats:italic> = 0.69, 95% <jats:italic>CI<\/jats:italic> = 0.36 to 1.31, <jats:italic>p<\/jats:italic> = 0.25), and parathyroidectomy (<jats:italic>RR<\/jats:italic> = 0.36, 95% <jats:italic>CI<\/jats:italic> = 0.09 to 1.35, <jats:italic>p<\/jats:italic> = 0.13) between the Cinacalcet and non-Cinacalcet users. Moreover, Cinacalcet was associated with an increased risk of nausea (<jats:italic>RR<\/jats:italic> = 2.29, 95% <jats:italic>CI<\/jats:italic> = 1.73 to 3.05, <jats:italic>p<\/jats:italic> = 0.001), hypocalcemia (<jats:italic>RR<\/jats:italic> = 4.05, 95% <jats:italic>CI<\/jats:italic> = 2.33 to 7.04, <jats:italic>p<\/jats:italic> = 0.001), and vomiting (<jats:italic>RR<\/jats:italic> = 1.90, 95% <jats:italic>CI<\/jats:italic> = 1.70 to 2.11, <jats:italic>p<\/jats:italic> = 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The number of publications indexed to Cinacalcet and SHPT has increased rapidly over the past 22 years. Literature distribution, research topics, and emerging trends in publications on Cinacalcet and SHPT were analyzed using a machine learning-based bibliometric review. The findings of this meta-analysis provide valuable insights into the efficacy and safety of cinacalcet for the treatment of SHPT, which will be of interest to both clinical and researchers.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1146955","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:55:24Z","timestamp":1689764124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Xiaosong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: review of the disease and its treatment","volume":"26","author":"De Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl718","article-title":"Mineral metabolism parameters throughout chronic kidney disease stages 1\u20135\u2014achievement of K\/DOQI target ranges","volume":"22","author":"Craver","year":"2007","journal-title":"Nephrol Dialysis Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/184321","article-title":"International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data","volume":"2015","author":"Hedgeman","year":"2015","journal-title":"Int J Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10157-016-1369-2","article-title":"Management of secondary hyperparathyroidism: how and why","volume":"21","author":"Komaba","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.5.709.63595","article-title":"Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"25","author":"Byrnes","year":"2005","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin d on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dialysis Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001436","article-title":"Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials","volume":"10","author":"Palmer","year":"2013","journal-title":"PloS Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2021.03.013","article-title":"Decreasing surgical management of secondary hyperparathyroidism in the United States","volume":"264","author":"Fligor","year":"2021","journal-title":"J Surg Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.xkme.2022.100475","article-title":"Etelcalcetide versus cinacalcet in hemodialysis patients in the United States: a facility calcimimetic approach to assess real-world effectiveness","volume":"4","author":"Karaboyas","year":"2022","journal-title":"Kidney Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001363","article-title":"Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower CardioVascular events (EVOLVE) trial","volume":"3","author":"Wheeler","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2215\/CJN.07730814","article-title":"The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"10","author":"Parfrey","year":"2015","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014040414","article-title":"Evaluation of cinacalcet HTCl therapy to lower cardiovascular events (EVOLVE) trial investigators: effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1002\/9783527681969","volume-title":"Handbook of bibliometric indicators: quantitative tools for studying and evaluating research","author":"Todeschini","year":"2016"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032747","article-title":"Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408398.2022.2067827","article-title":"Therapeutic role of curcumin in adult neurogenesis for management of psychiatric and neurological disorders: a scientometric study to an in-depth review","author":"Ma","year":"2022","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32995-7","article-title":"Factors affecting sex-related reporting in medical research: a cross-disciplinary bibliometric analysis","volume":"393","author":"Sugimoto","year":"2019","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: An r-tool for comprehensive science mapping Analysis","volume":"11","author":"Aria","year":"2018","journal-title":"J Informetrics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"Van Eck","year":"2010","journal-title":"scientometrics"},{"key":"B25","first-page":"1","article-title":"The citespace manual","volume":"1","author":"Chen","year":"2014","journal-title":"Coll Computing Inf"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1756284820934594","DOI":"10.1177\/1756284820934594","article-title":"A bibliometric analysis of 23,492 publications on rectal cancer by machine learning: basic medical research is needed","volume":"13","author":"Wang","year":"2020","journal-title":"Ther Adv Gastroenterol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.15265\/IY-2016-049","article-title":"Clinical natural language processing in 2015: leveraging the variety of texts of clinical interest","volume":"25","author":"N\u00e9v\u00e9ol","year":"2016","journal-title":"Yearbook Med Inf"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11423-020-09761-w","article-title":"Identifying patterns in students\u2019 scientific argumentation: content analysis through text mining using latent dirichlet allocation","volume":"68","author":"Xing","year":"2020","journal-title":"Educ Technol Res Dev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.3390\/rs13214414","article-title":"Research trends in the remote sensing of phytoplankton blooms: results from bibliometrics","volume":"13","author":"Li","year":"2021","journal-title":"Remote Sens"},{"key":"B30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1162\/jmlr.2003.3.4-5.993","article-title":"Latent dirichlet allocation","volume":"3","author":"Blei","year":"2003","journal-title":"J Mach Learn Res"},{"key":"B31","volume":"4","author":"Higgins","year":"2011","journal-title":"The cochrane collaboration. Cochrane handbook for systematic reviews of interventions"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/asi.20609","article-title":"What do we know about the h index","volume":"58","author":"Bornmann","year":"2007","journal-title":"J Am Soc Inf Sci Technol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.19173\/irrodl.v22i2.5358","article-title":"Investigation of emerging trends in the e-learning field using latent dirichlet allocation","volume":"22","author":"Gurcan","year":"2021","journal-title":"Int Rev Res Open Distributed Learn"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0319-7","article-title":"Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism","volume":"101","author":"Yu","year":"2017","journal-title":"Calcified Tissue Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01578-y","article-title":"Upacicalcet: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.05.84","article-title":"Efficacy and safety of cinacalcet and active vitamin d in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease: a network meta-analysis","volume":"7","author":"Ni","year":"2019","journal-title":"Ann Trans Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-019-02271-6","article-title":"Cinacalcet plus vitamin d versus vitamin d alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials","volume":"51","author":"Xu","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v10i3.3999","article-title":"The beneficial effect of paricalcitol (Zemplar) on secondary hyperparathyroidism refractory to calcitriol (Calcijex) and cinacalcet HCl (Mimpara) in patients on maintenance hemodialysis: a prospective and crossover study","volume":"10","author":"El-Reshaid","year":"2020","journal-title":"J Drug Delivery Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz021","article-title":"Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: mimosa study","volume":"12","author":"Rottembourg","year":"2019","journal-title":"Clin Kidney J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000504139","article-title":"Cinacalcet treatment significantly improves all-cause and cardiovascular survival in dialysis patients: results from a meta-analysis","volume":"44","author":"Zu","year":"2019","journal-title":"Kidney Blood Pressure Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12882-021-02312-2","article-title":"A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism","volume":"22","author":"Eddington","year":"2021","journal-title":"BMC Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ndt\/gfz159","article-title":"Cinacalcet use in paediatric dialysis: a position statement from the European society for paediatric nephrology and the chronic kidney disease-mineral and bone disorders working group of the ERA-EDTA","volume":"35","author":"Bacchetta","year":"2020","journal-title":"Nephrol Dialysis Transplant"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfp784","article-title":"The role of FGF-23 in CKD\u2013MBD and cardiovascular disease: friend or foe","volume":"25","author":"Larsson","year":"2010","journal-title":"Nephrol Dialysis Transplant"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease\u2013associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.466","article-title":"FGF23\u2013parathyroid interaction: implications in chronic kidney disease","volume":"77","author":"Komaba","year":"2010","journal-title":"Kidney Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-015-9318-z","article-title":"The PTH-vitamin d-FGF23 axis","volume":"16","author":"Blau","year":"2015","journal-title":"Rev Endocrine Metab Disord"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e328351a391","article-title":"Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease","volume":"21","author":"Isakova","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2011","journal-title":"Nephrol Dialysis Transplant"},{"key":"B49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1570161118666200420102100","article-title":"New insights into the role of FGF-23 and klotho in cardiovascular disease in chronic kidney disease patients","volume":"19","author":"Memmos","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-818540-7.00013-6","article-title":"Calcium, phosphate, PTH, vitamin d, and FGF-23 in CKD-mineral and bone disorder","author":"Bellorin-Font","year":"2022","journal-title":"Nutr Manage Renal Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11030175","article-title":"FGF23, biomarker or target","volume":"11","author":"Rodelo-Haad","year":"2019","journal-title":"Toxins (Basel)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1146955\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:55:31Z","timestamp":1689764131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1146955\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":52,"alternative-id":["10.3389\/fendo.2023.1146955"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1146955","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"article-number":"1146955"}}